Results 201 to 210 of about 4,034,895 (347)

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

open access: yesAdvanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin   +14 more
wiley   +1 more source

GSK-3β Regulates Tumor Stemness and Immune-Related Pathways in Triple-Negative Breast Cancer: A Bioinformatics and Experimental Validation Study

open access: yesThe Breast Journal
Ling Zhou   +9 more
doaj   +1 more source

Breast Surgery [PDF]

open access: yesBritish Journal of Cancer, 1982
openaire   +1 more source

Comparison of Survival Outcomes of Breast-Conserving Surgery Plus Radiotherapy with Mastectomy in Early Breast Cancer Patients: Less Is More? [PDF]

open access: gold
Chularat Duangkaew   +6 more
openalex   +1 more source

Combined thoracic paravertebral and pectoral nerve blocks for breast surgery under sedation: a prospective observational case series

open access: yesAnaesthesia, 2018
A. Pawa   +8 more
semanticscholar   +1 more source

HPD is an m6A Methyltransferase that Protects Colorectal Cancer Cells from Ferroptotic Cell Death by m6A Methylating SLC7A11/GPX4

open access: yesAdvanced Science, EarlyView.
This study reveals that the tyrosine metabolic enzyme HPD functions as a previously uncharacterized, METTL3‐independent m6A methyltransferase. It promotes colorectal tumor progression by coordinately regulating the SLC7A11/GPX4 axis to suppress ferroptosis.
Jiyan Wang   +17 more
wiley   +1 more source

Poly-4-hydroxybutyrate mesh (GalaFlex®) in aesthetic breast surgery: A comprehensive systematic review. [PDF]

open access: yesJPRAS Open
Palmesano M   +9 more
europepmc   +1 more source

Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

open access: yesNew England Journal of Medicine, 2002
U. Veronesi   +7 more
semanticscholar   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Mapping Implementation Strategies to Address Barriers to Commission on Cancer's Accreditation Standards in Breast Surgery. [PDF]

open access: yesJ Am Coll Surg
Hillas J   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy